# US 2026/0174780 A1 · Bismuth-thiol compositions and methods for treating inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0174780 A1
- Document ID: US20260174780A1
- Status: Published application
- Kind: A1
- Application number: 19/129,717
- Filed: 2023-11-15
- Published: 2026-06-25
- Earliest claimed: 2022-11-15
- Assignees: Microbion Corporation
- Applicants: Microbion Corporation
- Inventors: Brett Hugh James BAKER
- Web page: https://patentgrep.com/patent/US20260174780A1

## CPC

- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 9/1682: {Processes}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/06: Antipsoriatics
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to pravibismane compositions and their use in methods for treating inflammation-related diseases or conditions, such as an inflammatory disease of the lung, psoriasis, and acne vulgaris in a subject. Treatment of inflammation-related diseases and conditions according to the disclosed methods provides an increase in the expression of anti-inflammatory cytokines, including IL-10, and/or a decrease in the expression of one or more pro-inflammatory cytokines, such as one or more of IFN-γ, MIP-3a, MIP-1β, TNF-a, IL-22, IL-17A, IL-15, and IL-13.

## Claims

### Claim 1

A method of treating an inflammation-related and/or fibrotic disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of a bismuth-thiol (BT) composition comprising pravibismane, wherein the effective amount is effective in the subject to exert an anti-inflammatory effect by therapeutically:
modulating IL-10 levels; and/or,
modulating TNF-α levels; and/or,
inhibiting neutrophil-mediated inflammation/transmigration/infiltration; and/or,
inhibiting excessive or exuberant or pathological fibrosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the inflammation-related disease or condition is an autoimmune disease, a cardiovascular disease, sepsis, a gastrointestinal disorder, a metabolic disease, a liver disease, a neurodegenerative disease, an inflammatory disease of the lung, or an inflammatory condition of the skin.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the inflammation-related disease is rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis, the cardiovascular disease is heart disease, the inflammatory disease of the lung is chronic obstructive pulmonary disease (COPD) or asthma, the gastrointestinal disorder is ulcerative colitis or Crohn's disease, the metabolic disease is type-2 diabetes, the liver disease is nonalcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), the neurodegenerative disease is Parkinson's disease or Alzheimer's disease, the inflammatory disease of the skin is acne vulgaris, atopic dermatitis, or psoriasis.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the inflammation-related disease or condition is an inflammatory disease or condition of the skin.

### Claim 5 (depends on 4)

The method of claim 4, wherein the inflammatory disease or condition of the skin is psoriasis or acne vulgaris.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the inflammatory disease or condition of the skin is psoriasis or eczema.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The methods of any one of the claims 1-6, wherein the inflammation-related and/or fibrotic disease is an inflammatory arthritide such as arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The methods of any one of the claims 1-6, wherein the pulmonary inflammatory and/or fibrotic disease is cystic fibrosis (CF), chronic rhinosinusitis, nasal polyps, asthma, non-CF bronchiectasis, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis associated interstitial lung disease, pulmonary fibrosis associated with rheumatoid arthritis, and VEXAS Syndrome.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The methods of any one of claims 1-8, wherein the gastrointestinal inflammatory and/or fibrotic disease is infectious colitis, Crohn's Disease, Bowel-Associated Dermatosis-Arthritis Syndrome (BADAS), ulcerative colitis, and inflammatory bowel disease (IBD).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The methods of any one of claims 1-9, wherein the cardiovascular inflammatory and/or fibrotic disease is cardiac fibrosis, myocarditis, atherosclerosis, and aortic aneurysm.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The methods of any one of claims 1-10, wherein the metabolic inflammatory and/or fibrotic disease is diabetes, e.g., type-2 diabetes.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The methods of any one of claims 1-11, wherein the liver inflammatory and/or fibrotic disease is a fatty liver disease, e.g., nonalcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The methods of any one of claims 1-12, wherein the neurodegenerative inflammatory and/or fibrotic disease is Parkinson's disease, multiple sclerosis, fibromyalgia, neuro-neutrophilic disease, or Alzheimer's disease or the musculoskeletal inflammatory and/or fibrotic disease is gout and polychrondritis.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13, wherein modulating IL-10 levels comprises increasing IL-10 production in the subject.

### Claim 15 (depends on 14)

The method of claim 14 wherein the subject exhibits a reduced IL-10 expression relative to a subject not afflicted with the inflammation-related disease or condition.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15, wherein modulating TNF-α levels comprises decreasing TNF-α production in the subject.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the inflammation-related disease or condition is a disease or condition responsive to an increased level of IL-10.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1 to 17, wherein the inflammation-related disease or condition is a neutrophil-mediated or neutrophil-dominant disease or condition, wherein the effective amount is effective to reduce migration of neutrophils into a target tissue and thereby inhibit neutrophil-mediated inflammation/transmigration/infiltration.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein the inflammation-related disease or condition comprises a wound, and the effective amount is effective to mediate wound healing of the wound.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the pravibismane is provided in a composition comprising a plurality of particles of pravibismane suspended therein, wherein the particles have a D90 of less than about 5 μm.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the particles have a D90 of less than about 2 μm and/or the D50 of said particles is less than or equal to about 1.0 μm.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the effective amount is effective to modulate an innate immune activation.

### Claim 23

The method of any one of the preceding claims, wherein pravibismane is provided in a composition that further comprises about 0.05% to about 1.0% polysorbate 80, optionally about 0.05 to 40 mM sodium chloride, optionally about 1% to about 10% of methylcellulose, and optionally about 2 to 20 mM sodium phosphate at about pH 7.4.

### Claim 24

The method of any one of the preceding claims, wherein the pravibismane is administered three times per day, two times per day, once daily, every other day, once every three days, three times per week, once every week, once every other week, once every month, or once every other month.

### Claim 25

The method of any one of the preceding claims, wherein the pravibismane is administered topically or by inhalation.

### Claim 26

The method of any one of the preceding claims, wherein the pravibismane is administered orally or systemically.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1 to 26 treating an inflammation-related disease or condition is regulated by or associated with the activation of an inflammasome.

### Claim 28 (depends on 27)

The method of claim 27, wherein the inflammasome is the NLRP3 inflammasome or the AIM2 inflammasome.

### Claim 29 (depends on 28)

The method of claim 28, wherein the inflammasome is the NLRP3 inflammasome.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the pravibismane is effective to inhibit expression of the inflammasome.

### Claim 31 (depends on 30)

The method of claim 30, wherein the inhibited inflammasome is the NLRP3 inflammasome or the AIM2 inflammasome.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1 to 31, wherein the subject is a patient not diagnosed as having a microbial infection.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the effective amount of pravibismane is effective to prevent, reduce, or treat a microbial infection, or to reduce microbial products in the subject.

### Claim 34 (depends on 33)

The method of claim 33, wherein the microbial products comprise biofilms and/or superantigens.

### Claim 35 (depends on 34)

The method of claim 34, wherein the microbial infection in the subject is at least partially located in the inflammasome-expressing cells of the subject.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The method of any one of claims 30-35, wherein the inflammasome-expressing cells are macrophages, white blood cells, bronchial epithelial cells, alveolar epithelial cells, or combinations thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the inflammasome-expressing cells are macrophages.

### Claim 38 (depends on 36, 37)

The method of claim 36 or 37, wherein the macrophages are THP-1 macrophages.

### Claim 39 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the effective amount of pravibismane is effective to reduce the microbial infection in the inflammasome-expressing cells is reduced.

### Claim 40 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 27-39, wherein only cells of the subject that have a microbial infection exhibit increased inflammasome release.

### Claim 41 (depends on 40)

The method of claim 40, wherein the release of the NLRP3 inflammasome and/or the AIM2 inflammasome is increased.

### Claim 42 (depends on 41)

The method of claim 41, wherein the release of the NLRP3 inflammasome is increased.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 1-42, wherein the inflammation-related disease or condition is regulated by or associated with the activation of one or more cytokines.

### Claim 44 (depends on 43)

The method of claim 43, wherein the one or more cytokines is a pro-inflammatory cytokine selected from one of more IFN-γ, MIP-3α, MIP-1β, TNF-α, IL-22, IL-17A, IL-15, and IL-13.

### Claim 45 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 27-44, wherein the administering of pravibismane decreases expression of NLRP3 and/or AIM2 inflammasomes.

### Claim 46 (depends on 45)

The method of claim 45, wherein the expression of the NLRP3 and/or AIM2 inflammasomes is decreased by about 50%.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1 to 46, wherein the effective amount of pravibismane is effective to inhibit neutrophil-mediated inflammation/transmigration/infiltration.

### Claim 48 (depends on 47)

The method of claim 47, wherein the effective amount of pravibismane is effective to reduce the transmigration or recruitment of leukocytes in a target tissue that is a site of inflammation.

### Claim 49 (depends on 47)

The method of claim 47, wherein the site of inflammation in the subject has a decreased number of leukocytes after administration of pravibismane to the subject.

### Claim 50 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the production of IL-10 in the subject is increased after administration of the pravibismane to the subject.

### Claim 51 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the administration of pravibismane results in a decrease in the secretion of IFN-γ, MIP-3α, MIP-1β, TNF-α, IL-22, IL-17A, IL-15, IL-13, and TGF-β.

### Claim 52 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the administration of pravibismane results in an increase in the secretion of IL-2 in the cell of a subject.

### Claim 53 (depends on 47, 48, 49)

The method of any one of claims 47-49, wherein the leukocytes are neutrophils.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1-53, wherein the administration of the pravibismane results in a decrease in the secretion of one or more additional pro-inflammatory cytokines.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein the administration of the pravibismane results in a decrease in the secretion of IFN-γ, MIP-3α, MIP-103, TNF-α, IL-22, IL-17A, IL-15, IL-13 and/or TGF-β compared to a subject not administered the pravibismane.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 1-55, wherein the administration of pravibismane results in a decrease in the secretion of MIP-3α, MIP-1β, and/or TNF-α compared to a subject not administered the pravibismane.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 1-56, wherein the administration of the pravibismane results in a decrease in the secretion of TNF-α compared to a subject not administered the pravibismane.

### Claim 58 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein the secretion of IFN-γ, MIP-3α, MIP-1β, TNF-α, IL-22, IL-17A, IL-15, and/or IL-13 is decreased by about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a subject not administered the pravibismane.

### Claim 59 (depends on 55, 56, 57)

The method of any one of claims 55-57, wherein the secretion of IFN-γ, MIP-3α, MIP-1β, TNF-α, IL-22, IL-17A, IL-15, and/or IL-13 is decreased by about 3-fold compared to a subject not administered pravibismane.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the administration of the pravibismane to a subject results in an increase in the secretion of one or more additional anti-inflammatory cytokines.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 1-60, wherein the administration of the pravibismane to a subject results in an increase in the secretion of IL-2 compared to a subject not administered the pravibismane.

### Claim 62 (depends on 61)

The method of claim 61, wherein the secretion of IL-2 is increased by about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold compared to a subject not administered the pravibismane.

### Claim 63 (depends on 61)

The method of claim 61, wherein the secretion of IL-2 is increased by about 3-fold compared to a subject not administered the pravibismane.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1 to 63, wherein the disease or condition is an epithelial tissue disease or condition of an epithelial tissue, optionally wherein the pravibismane is administered to the epithelial tissue.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1 to 63, wherein the disease or condition is a dermatological disease or condition of a dermatological tissue, optionally wherein the pravibismane is administered to the dermatological tissue.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1 to 63, wherein the disease or condition is a lung disease or condition of a lung tissue, optionally wherein the pravibismane is administered to the lung tissue.
